{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447611733
| IUPAC_name = 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
| image = lidoflazine.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|lidoflazine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL         / P       / POM / CD -->
| legal_US = <!-- OTC                   / Rx-only  -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3416-26-0
| ATC_prefix = C08
| ATC_suffix = EX01
| PubChem = 3926
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J4ZHN3HBTE
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04733
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 3789

<!--Chemical data-->
| C=30 | H=35 | F=2 | N=3 | O=1 
| molecular_weight = 491.615 g/mol
| melting_point = 159
| melting_high = 161
| solubility = Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%);
| smiles            = CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = ZBIAKUMOEKILTF-UHFFFAOYSA-N
}}
'''Lidoflazine''' is a [[piperazine]] [[calcium channel blocker]]. It is a coronary vasodilator with some antiarrhythmic action.<ref name="JPET">{{Cite journal
 | title = The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator
 | url = http://jpet.aspetjournals.org/cgi/content/abstract/152/2/265
 | year = 1966
 | journal = Journal of Pharmacology and Experimental Therapeutics
 | pages = 265â€“274
 | volume = 152
 | issue = 2
 | last1 = Schaper	 | first1 =  W.K.A.
 | last2 =  Xhonneux	 | first2 =  R.
 | last3 =  Jageneau	 | first3 =  A.H.M.
 | last4 =  Janssen	 | first4 =  P.A.J.
 | accessdate = 2009-06-20
 | pmid = 5944369	}}</ref> Lidoflazine was discovered at [[Janssen Pharmaceutica]] in 1964.

==Physical properties==
===Solubility  at room temperature===

Extracted from <ref>http://jpet.aspetjournals.org/cgi/content/abstract/152/2/265</ref>
{|  style="text-align: left; width: 350px; height: 150px;" border="1" cellpadding="2" cellspacing="2" 
|  colspan="1" rowspan="2"style="vertical-align: top; text-align: center;" | Solvent
|  colspan="2" style="vertical-align: top; text-align: center;" | 0.01
N
|  colspan="2" style="vertical-align: top; text-align: center;" | 0.1
N
|- 
|  style="vertical-align: top;" |
|  style="vertical-align: top; text-align: center;" | %
|  style="vertical-align: top; text-align: center;" | pH
|  style="vertical-align: top; text-align: center;" | %
|  style="vertical-align: top; text-align: center;" | pH
|- 
|  style="vertical-align: top;" | Hydrochloric Acid
|  style="vertical-align: top;" | 0.4
|  style="vertical-align: top;" | 3.0
|  style="vertical-align: top;" | 0.7
|  style="vertical-align: top;" | 1.9
|- 
|  style="vertical-align: top;" | Tartaric Acid
|  style="vertical-align: top;" | 0.3
|  style="vertical-align: top;" | 3.1
|  style="vertical-align: top;" | 1.0
|  style="vertical-align: top;" | 2.5
|- 
|  style="vertical-align: top;" | Citric Acid
|  style="vertical-align: top;" | 0.3
|  style="vertical-align: top;" | 3.1
|  style="vertical-align: top;" | 0.5
|  style="vertical-align: top;" | 2.5
|- 
|  style="vertical-align: top;" | Lactic Acid
|  style="vertical-align: top;" | 0.2
|  style="vertical-align: top;" | 3.4
|  style="vertical-align: top;" | 0.7
|  style="vertical-align: top;" | 2.9
|- 
|  style="vertical-align: top;" | Acetic Acid
|  style="vertical-align: top;" | 0.1
|  style="vertical-align: top;" | 3.5
|  style="vertical-align: top;" | 0.4
|  style="vertical-align: top;" | 3.8
|}

==References==
{{Reflist}}
* Schaper WK, Xhonneux R, Jageneau AH., Stimulation of the coronary collateral circulation by lidoflazine (R 7904), Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965 November 4;252(1):1-8.

{{Calcium channel blockers}}
{{Piperazines}}

[[Category:Piperazines]]
[[Category:Calcium channel blockers]]
[[Category:Acetanilides]]
[[Category:Fluoroarenes]]
[[Category:Janssen Pharmaceutica]]
[[Category:Belgian inventions]]


{{cardiovascular-drug-stub}}